MK-1084

Phase 2Small molecule

Merck & Co.

MK-1084 is one of 41 small molecule programs targeting Malignant Neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant NeoplasmRecruiting

Metastatic Solid TumorsActive, not recruiting

Lung Neoplasm MalignantRecruiting

Malignant NeoplasmPhase 2

Recruiting

Metastatic Solid TumorsPhase 1

Active, not recruiting

Lung Neoplasm MalignantPreclinical

Recruiting

Competition

Competitive Landscape

41 competitors in Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Approved

2 2

Opdivo

Bristol-Myers Squibb

Phase 2

6 3

Tagrisso

AstraZeneca

Phase 2

1 4

Keytruda

Merck & Co.

Phase 1

3 5

Actemra

CCelltrion

Phase 1

1 6

MK-1084

Merck & Co.

Phase 2

1 7

SSGJ-705

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 2

1 8

SSGJ-612

SShenyang Sunshine Pharmaceutical Co., LTD.

Phase 2

1 9

Poly ICLC

CCelldex Therapeutics

Phase 1

1 10

SSGJ-705 Combined With Chemotherapy

SShenyang Sunshine Pharmaceutical Co., LTD.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

Metastatic Solid Tumors

NCT05853367

Q2 2032

PreclinicalRecruiting

Lung Neoplasm Malignant

NCT07286149

Phase 2Recruiting

Malignant Neoplasm

NCT07252739

Q4 2039

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT07431827

Clinical

Trials by Indication[1]

Absorption1 trial

A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06687759·8 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07431827·400 enrolled

Lung Neoplasm Malignant1 trial

KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07286149·140 enrolled

Malignant Neoplasm1 trial

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07252739·140 enrolled

Metastatic Solid Tumors1 trial

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT05853367·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MK-1084. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-1084 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-1084. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

MK-1084

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2032

Q4 2039

Trials by Indication[1]

Absorption1 trial

Non-Small Cell Lung Cancer1 trial

Lung Neoplasm Malignant1 trial

Malignant Neoplasm1 trial

Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News